Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia

Expert Opinion on Biological Therapy
Johan VansteenkisteMaryAnn Foote

Abstract

Chemotherapy-induced anaemia has important consequences on the quality of life and social function of cancer patients. The finding of erythropoietin (EPO) deficiency in these patients led to the therapeutic development of erythropoietic proteins. Darbepoetin alfa (Aranesp), Amgen Inc, Thousand Oaks, California), a new erythropoietic growth factor, has eight more sialic acids than epoetin alfa. The increased sialic acid content confers a three-fold longer half-life and allows the drug to be administered less frequently than epoetin alfa. Darbepoetin alfa affects the same early haematopoietic cells as epoetin alfa and the endogenous hormone EPO. Preclinical pharmacokinetic studies suggest that the intrinsic pharmacological properties of darbepoetin alfa are comparable to those of epoetin alfa, but that the increased sialic acid content allows for less-frequent administration with superior performance. Darbepoetin alfa has been shown to have safe clinical efficacy in a variety of tumour settings and with several types of chemotherapy.

References

Jul 1, 1988·The Journal of Clinical Investigation·M J KouryS T Sawyer
Sep 1, 1987·American Journal of Clinical Pathology·R H Walker
May 1, 1980·British Journal of Haematology·A J ErslevR Silver
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GlaspyS Vadhan-Raj
Feb 11, 1999·The New England Journal of Medicine·L T GoodnoughJ P AuBuchon
Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Jul 29, 2000·Cancer Treatment Reviews·S MercadanteS Filosto
Nov 9, 2000·Seminars in Hematology·G A Curt
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LittlewoodUNKNOWN Epoetin Alfa Study Group
Jul 28, 2001·Kidney International·F LocatelliUNKNOWN European/Australian NESP 980202 Study Group
Feb 15, 2002·The New England Journal of Medicine·Nicole CasadevallPatrick Mayeux
May 17, 2002·The New England Journal of Medicine·Sharon K GershonM Miles Braun
Aug 22, 2002·Journal of the National Cancer Institute·Johan VansteenkisteUNKNOWN Aranesp 980297 Study Group
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Clinical Oncology. American Society of Hematology
Oct 3, 2002·British Journal of Haematology·Michael HedenusUNKNOWN Darbepoetin alfa 990114 Study Group
Mar 4, 2003·Nature Biotechnology·Steve ElliottJoan Egrie

❮ Previous
Next ❯

Citations

Nov 23, 2006·Cancer·Pilar GiraldoUNKNOWN Aranesp in Myelodysplastic Syndromes (ARM) Study Group
Dec 8, 2009·Medicinal Research Reviews·Ainhoa MuruaJosé Luis Pedraz
Dec 4, 2003·Expert Opinion on Pharmacotherapy·Johan Vansteenkiste, Johan Van-Steenkiste
Mar 30, 2005·Expert Opinion on Pharmacotherapy·Johan Vansteenkiste, Isabelle Wauters
Sep 25, 2004·Medicinal Research Reviews·Michele BuemiGiovanni Grasso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Expert Opinion on Pharmacotherapy
Johan Vansteenkiste, Isabelle Wauters
Expert Opinion on Pharmacotherapy
Johan Vansteenkiste, Johan Van-Steenkiste
International Journal of Clinical Pharmacology and Therapeutics
G MicieliG Nappi
© 2022 Meta ULC. All rights reserved